Keyword: Antibody-Drug Conjugates (ADC)


Daiichi Sankyo and Merck & Co. Collaborate on Three DXd ADCs Worldwide

20.10.2023 -

Daiichi Sankyo and Merck & Co. to co-develop and commercialize three of Daiichi Sankyo’s DXd antibody-drug conjugate (ADC) candidates worldwide except for Japan where...


EU Commission Approves Pfizer’s Takeover of Seagen

20.10.2023 -

The US pharmaceutical company Pfizer has been cleared to acquire Seagen, a biotech company focused on developing cancer treatments.


Lonza Increases Capacity for Antibody-Drug Conjugates at Visp, Switzerland

06.10.2023 -

Swiss contract development and manufacturing organization (CDMO) Lonza is extending a long-term collaboration with an unnamed major global biopharmaceutical partner...


Wuxi Biologics Plans Spin-off and Separate Listing of Wuxi XDC

14.07.2023 -

Chinese contract research, development, and manufacturing organization (CRDMO) Wuxi Biologics announced the planned spin-off and separate listing of its subsidiary WuXi...


Olon Builds Second Plant for Ultra-Potent Compounds

05.06.2023 -

Italian API producer Olon has started building a second facility at its Rodano site in Milan that will be entirely dedicated to producing ultra-potent compounds.


BioNTech and DualityBio Sign ADC Rights Deal

14.04.2023 -

German biotech and Covid vaccine maker BioNTech has sealed a major deal with Chinese biotech DualityBio to co-develop and commercialize two cancer antibody drug...


Pfizer Takes Seagen for $43 Billion

15.03.2023 -

Pfizer has agreed to acquire Seagen, a global biotech focused on developing cancer treatments, for $43 billion. The announcement comes just a couple of weeks after the...

Chemistry & Life Sciences

Integrated Drug Development Models

13.05.2022 -

Interview with Giovanna Libralon, Senior Director Commercial Development Small Molecules at Lonza.